Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease
Identifieur interne : 001560 ( Main/Corpus ); précédent : 001559; suivant : 001561Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease
Auteurs : James F. Morley ; Daniel Weintraub ; Eugenia Mamikonyan ; Paul J. Moberg ; Andrew D. Siderowf ; John E. DudaSource :
- Movement Disorders [ 0885-3185 ] ; 2011-09.
English descriptors
Abstract
Hyposmia, psychiatric disorders, and cognitive problems are common nonmotor manifestations in Parkinson's disease, but how they are related remains unclear. We investigated the relationship between olfactory dysfunction and neuropsychiatric manifestations and performed a cross‐sectional study of 248 patients at two movement disorders clinics at academic medical centers. Psychiatric measures were the Geriatric Depression Scale‐15, Inventory of Depressive Symptomatology, State Anxiety Inventory, Apathy Scale, and Parkinson's Psychosis Rating Scale. Cognitive measures were the Mini–Mental State Examination, Hopkins Verbal Learning Test–Revised, Digit Span, Tower of London‐Drexel, and the Stroop Color Word Test. Olfaction was tested with the University of Pennsylvania Smell Identification Test. There was no significant association between olfaction and mood measures, but psychotic symptoms were more common in patients with olfaction scores below the median (30% vs. 12%; P < 0.001). Worse olfaction was associated with poorer memory (Hopkins Verbal Learning Test–Revised delayed recall items: mean [standard deviation], 6.2 [3.2] vs. 8.4 [2.8]; P < 0.001) and executive performance (Tower of London total moves, 52 [38] vs. 34 [21]; P < 0.001). Odor‐identification score was a significant predictor of abnormal performance on these cognitive tests after adjustment for age, sex, and disease characteristics in logistic regression models. The relationship between hyposmia, psychosis, and specific cognitive impairments may reflect the anatomic distribution of Lewy pathology and suggests that olfactory dysfunction could be a biomarker of additional extranigral disease. Future prospective studies are warranted to assess whether hyposmia, a very early feature of Parkinson's disease, might be used to predict the appearance of other common nonmotor symptoms. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23792
Links to Exploration step
ISTEX:C227001677EA3FFDB8C515D549210D0B6D05F7D6Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease</title><author><name sortKey="Morley, James F" sort="Morley, James F" uniqKey="Morley J" first="James F." last="Morley">James F. Morley</name><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Mental Illness Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</mods:affiliation></affiliation></author><author><name sortKey="Mamikonyan, Eugenia" sort="Mamikonyan, Eugenia" uniqKey="Mamikonyan E" first="Eugenia" last="Mamikonyan">Eugenia Mamikonyan</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation></author><author><name sortKey="Moberg, Paul J" sort="Moberg, Paul J" uniqKey="Moberg P" first="Paul J." last="Moberg">Paul J. Moberg</name><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation></author><author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation></author><author><name sortKey="Duda, John E" sort="Duda, John E" uniqKey="Duda J" first="John E." last="Duda">John E. Duda</name><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C227001677EA3FFDB8C515D549210D0B6D05F7D6</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23792</idno><idno type="url">https://api.istex.fr/document/C227001677EA3FFDB8C515D549210D0B6D05F7D6/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001560</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease</title><author><name sortKey="Morley, James F" sort="Morley, James F" uniqKey="Morley J" first="James F." last="Morley">James F. Morley</name><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Mental Illness Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</mods:affiliation></affiliation></author><author><name sortKey="Mamikonyan, Eugenia" sort="Mamikonyan, Eugenia" uniqKey="Mamikonyan E" first="Eugenia" last="Mamikonyan">Eugenia Mamikonyan</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation></author><author><name sortKey="Moberg, Paul J" sort="Moberg, Paul J" uniqKey="Moberg P" first="Paul J." last="Moberg">Paul J. Moberg</name><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation></author><author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation></author><author><name sortKey="Duda, John E" sort="Duda, John E" uniqKey="Duda J" first="John E." last="Duda">John E. Duda</name><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-09">2011-09</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="2051">2051</biblScope><biblScope unit="page" to="2057">2057</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C227001677EA3FFDB8C515D549210D0B6D05F7D6</idno><idno type="DOI">10.1002/mds.23792</idno><idno type="ArticleID">MDS23792</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>cognitive symptoms</term><term>nonmotor symptoms</term><term>olfaction</term><term>psychiatric symptoms</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hyposmia, psychiatric disorders, and cognitive problems are common nonmotor manifestations in Parkinson's disease, but how they are related remains unclear. We investigated the relationship between olfactory dysfunction and neuropsychiatric manifestations and performed a cross‐sectional study of 248 patients at two movement disorders clinics at academic medical centers. Psychiatric measures were the Geriatric Depression Scale‐15, Inventory of Depressive Symptomatology, State Anxiety Inventory, Apathy Scale, and Parkinson's Psychosis Rating Scale. Cognitive measures were the Mini–Mental State Examination, Hopkins Verbal Learning Test–Revised, Digit Span, Tower of London‐Drexel, and the Stroop Color Word Test. Olfaction was tested with the University of Pennsylvania Smell Identification Test. There was no significant association between olfaction and mood measures, but psychotic symptoms were more common in patients with olfaction scores below the median (30% vs. 12%; P < 0.001). Worse olfaction was associated with poorer memory (Hopkins Verbal Learning Test–Revised delayed recall items: mean [standard deviation], 6.2 [3.2] vs. 8.4 [2.8]; P < 0.001) and executive performance (Tower of London total moves, 52 [38] vs. 34 [21]; P < 0.001). Odor‐identification score was a significant predictor of abnormal performance on these cognitive tests after adjustment for age, sex, and disease characteristics in logistic regression models. The relationship between hyposmia, psychosis, and specific cognitive impairments may reflect the anatomic distribution of Lewy pathology and suggests that olfactory dysfunction could be a biomarker of additional extranigral disease. Future prospective studies are warranted to assess whether hyposmia, a very early feature of Parkinson's disease, might be used to predict the appearance of other common nonmotor symptoms. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>James F. Morley MD, PhD</name><affiliations><json:string>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</json:string><json:string>Department of Neurology, University of Pennsylvania, Philadelphia, PA</json:string></affiliations></json:item><json:item><name>Daniel Weintraub MD</name><affiliations><json:string>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</json:string><json:string>Department of Neurology, University of Pennsylvania, Philadelphia, PA</json:string><json:string>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</json:string><json:string>Mental Illness Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</json:string></affiliations></json:item><json:item><name>Eugenia Mamikonyan MS</name><affiliations><json:string>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</json:string></affiliations></json:item><json:item><name>Paul J. Moberg PhD</name><affiliations><json:string>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</json:string><json:string>Department of Neurology, University of Pennsylvania, Philadelphia, PA</json:string><json:string>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</json:string></affiliations></json:item><json:item><name>Andrew D. Siderowf MD</name><affiliations><json:string>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</json:string><json:string>Department of Neurology, University of Pennsylvania, Philadelphia, PA</json:string></affiliations></json:item><json:item><name>John E. Duda MD</name><affiliations><json:string>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</json:string><json:string>Department of Neurology, University of Pennsylvania, Philadelphia, PA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>olfaction</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>nonmotor symptoms</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>psychiatric symptoms</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cognitive symptoms</value></json:item></subject><articleId><json:string>MDS23792</json:string></articleId><language><json:string>eng</json:string></language><abstract>Hyposmia, psychiatric disorders, and cognitive problems are common nonmotor manifestations in Parkinson's disease, but how they are related remains unclear. We investigated the relationship between olfactory dysfunction and neuropsychiatric manifestations and performed a cross‐sectional study of 248 patients at two movement disorders clinics at academic medical centers. Psychiatric measures were the Geriatric Depression Scale‐15, Inventory of Depressive Symptomatology, State Anxiety Inventory, Apathy Scale, and Parkinson's Psychosis Rating Scale. Cognitive measures were the Mini–Mental State Examination, Hopkins Verbal Learning Test–Revised, Digit Span, Tower of London‐Drexel, and the Stroop Color Word Test. Olfaction was tested with the University of Pennsylvania Smell Identification Test. There was no significant association between olfaction and mood measures, but psychotic symptoms were more common in patients with olfaction scores below the median (30% vs. 12%; P > 0.001). Worse olfaction was associated with poorer memory (Hopkins Verbal Learning Test–Revised delayed recall items: mean [standard deviation], 6.2 [3.2] vs. 8.4 [2.8]; P > 0.001) and executive performance (Tower of London total moves, 52 [38] vs. 34 [21]; P > 0.001). Odor‐identification score was a significant predictor of abnormal performance on these cognitive tests after adjustment for age, sex, and disease characteristics in logistic regression models. The relationship between hyposmia, psychosis, and specific cognitive impairments may reflect the anatomic distribution of Lewy pathology and suggests that olfactory dysfunction could be a biomarker of additional extranigral disease. Future prospective studies are warranted to assess whether hyposmia, a very early feature of Parkinson's disease, might be used to predict the appearance of other common nonmotor symptoms. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>7.447</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1902</abstractCharCount><pdfWordCount>4447</pdfWordCount><pdfCharCount>30614</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>260</abstractWordCount></qualityIndicators><title>Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>7</total><last>2057</last><first>2051</first></pages><issn><json:string>0885-3185</json:string></issn><issue>11</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23792</json:string></doi><id>C227001677EA3FFDB8C515D549210D0B6D05F7D6</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/C227001677EA3FFDB8C515D549210D0B6D05F7D6/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/C227001677EA3FFDB8C515D549210D0B6D05F7D6/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/C227001677EA3FFDB8C515D549210D0B6D05F7D6/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Funding agencies: This work was supported by NIH grant K23 MH067894 (to D.W.).</note><note type="content">*Relevant conflicts of interest/financial disclosures: Dr. Morley has received travel funding from Teva Pharmaceutical Industries Ltd. Dr. Weintraub has served on a scientific advisory board for Boehringer Ingelheim; serves on the editorial board of Movement Disorders; has received speaker honoraria from Boehringer Ingelheim, ACADIA Pharmaceuticals, Novartis, Osmotica Pharmaceutical Corp., BrainCells Inc., Merck Serono, Sanofi‐aventis, and Pfizer Inc; and has received/receives research support from Avid Radiopharmaceuticals, Inc., Boehringer Ingelheim, National Institutes of Health (NIMH K23 MH067894 [PI], NINDS P50 NS053488‐01 [coinvestigator], NIA RO1AG031348 [site PI], and NINDS R01NS065087 [coinvestigator]), and from the Michael J. Fox Foundation for Parkinson's Research. Ms. Mamikonyan reports no disclosures. Dr. Siderowf serves on a scientific advisory board for, and has received speaker honoraria from, Teva Pharmaceutical Industries Ltd.; serves as a consultant for Supernus Pharmaceuticals, Inc.; and receives research support from Avid Radiopharmaceuticals, Inc., the NIH (NINDS U10 NS044451‐023 [Site PI], NINDS P50 NS053488‐01 [cocore leader and project leader], NINDS R43NS0636071 [site PI], and NINDS R01NS065087 [coinvestigator]), and from the Institute for Neurodegenerative Disorders. Dr. Duda serves on a grant review panel for the Michael J. Fox Foundation for Parkinson's Research; receives research support from the U.S. Department of Veterans Affairs (Merit Award [PI]), the Michael J. Fox Foundation, and the Samueli Institute; and holds stock in C.R. Bard, Inc., Celgene, Clarient, Inc., and Johnson & Johnson. Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease</title><author><persName><forename type="first">James F.</forename><surname>Morley</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</affiliation></author><author><persName><forename type="first">Daniel</forename><surname>Weintraub</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</affiliation><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</affiliation><affiliation>Mental Illness Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</affiliation></author><author><persName><forename type="first">Eugenia</forename><surname>Mamikonyan</surname></persName><roleName type="degree">MS</roleName><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</affiliation></author><author><persName><forename type="first">Paul J.</forename><surname>Moberg</surname></persName><roleName type="degree">PhD</roleName><affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</affiliation><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</affiliation></author><author><persName><forename type="first">Andrew D.</forename><surname>Siderowf</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</affiliation></author><author><persName><forename type="first">John E.</forename><surname>Duda</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Philadelphia Veterans Administration Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104</p></note><affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-09"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="2051">2051</biblScope><biblScope unit="page" to="2057">2057</biblScope></imprint></monogr><idno type="istex">C227001677EA3FFDB8C515D549210D0B6D05F7D6</idno><idno type="DOI">10.1002/mds.23792</idno><idno type="ArticleID">MDS23792</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Hyposmia, psychiatric disorders, and cognitive problems are common nonmotor manifestations in Parkinson's disease, but how they are related remains unclear. We investigated the relationship between olfactory dysfunction and neuropsychiatric manifestations and performed a cross‐sectional study of 248 patients at two movement disorders clinics at academic medical centers. Psychiatric measures were the Geriatric Depression Scale‐15, Inventory of Depressive Symptomatology, State Anxiety Inventory, Apathy Scale, and Parkinson's Psychosis Rating Scale. Cognitive measures were the Mini–Mental State Examination, Hopkins Verbal Learning Test–Revised, Digit Span, Tower of London‐Drexel, and the Stroop Color Word Test. Olfaction was tested with the University of Pennsylvania Smell Identification Test. There was no significant association between olfaction and mood measures, but psychotic symptoms were more common in patients with olfaction scores below the median (30% vs. 12%; P < 0.001). Worse olfaction was associated with poorer memory (Hopkins Verbal Learning Test–Revised delayed recall items: mean [standard deviation], 6.2 [3.2] vs. 8.4 [2.8]; P < 0.001) and executive performance (Tower of London total moves, 52 [38] vs. 34 [21]; P < 0.001). Odor‐identification score was a significant predictor of abnormal performance on these cognitive tests after adjustment for age, sex, and disease characteristics in logistic regression models. The relationship between hyposmia, psychosis, and specific cognitive impairments may reflect the anatomic distribution of Lewy pathology and suggests that olfactory dysfunction could be a biomarker of additional extranigral disease. Future prospective studies are warranted to assess whether hyposmia, a very early feature of Parkinson's disease, might be used to predict the appearance of other common nonmotor symptoms. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>olfaction</term></item><item><term>nonmotor symptoms</term></item><item><term>psychiatric symptoms</term></item><item><term>cognitive symptoms</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-12-08">Received</change><change when="2011-04-18">Registration</change><change when="2011-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/C227001677EA3FFDB8C515D549210D0B6D05F7D6/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="110"><doi origin="wiley" registered="yes">10.1002/mds.v26.11</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">11</numbering></numberingGroup><coverDate startDate="2011-09">September 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="160" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23792</doi><idGroup><id type="unit" value="MDS23792"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-12-08"></event><event type="manuscriptRevised" date="2011-04-11"></event><event type="manuscriptAccepted" date="2011-04-18"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.10 mode:FullText" date="2011-09-19"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-05-24"></event><event type="firstOnline" date="2011-05-24"></event><event type="publishedOnlineFinalForm" date="2011-09-19"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2051</numbering><numbering type="pageLast">2057</numbering></numberingGroup><correspondenceTo>Philadelphia Veterans Administration Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23792.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="53"></count><count type="wordTotal" number="5900"></count></countGroup><titleGroup><title type="main" xml:lang="en">Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease<link href="#fn1"></link><link href="#fn2"></link></title><title type="short" xml:lang="en">Hyposmia and Neuropsychiatric Problems in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>James F.</givenNames><familyName>Morley</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2 #af3 #af4"><personName><givenNames>Daniel</givenNames><familyName>Weintraub</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Eugenia</givenNames><familyName>Mamikonyan</familyName><degrees>MS</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af2 #af3"><personName><givenNames>Paul J.</givenNames><familyName>Moberg</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Andrew D.</givenNames><familyName>Siderowf</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>John E.</givenNames><familyName>Duda</familyName><degrees>MD</degrees></personName><contactDetails><email>John.Duda@va.gov</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Mental Illness Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">olfaction</keyword><keyword xml:id="kwd3">nonmotor symptoms</keyword><keyword xml:id="kwd4">psychiatric symptoms</keyword><keyword xml:id="kwd5">cognitive symptoms</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Hyposmia, psychiatric disorders, and cognitive problems are common nonmotor manifestations in Parkinson's disease, but how they are related remains unclear. We investigated the relationship between olfactory dysfunction and neuropsychiatric manifestations and performed a cross‐sectional study of 248 patients at two movement disorders clinics at academic medical centers. Psychiatric measures were the Geriatric Depression Scale‐15, Inventory of Depressive Symptomatology, State Anxiety Inventory, Apathy Scale, and Parkinson's Psychosis Rating Scale. Cognitive measures were the Mini–Mental State Examination, Hopkins Verbal Learning Test–Revised, Digit Span, Tower of London‐Drexel, and the Stroop Color Word Test. Olfaction was tested with the University of Pennsylvania Smell Identification Test. There was no significant association between olfaction and mood measures, but psychotic symptoms were more common in patients with olfaction scores below the median (30% vs. 12%; <i>P</i> < 0.001). Worse olfaction was associated with poorer memory (Hopkins Verbal Learning Test–Revised delayed recall items: mean [standard deviation], 6.2 [3.2] vs. 8.4 [2.8]; <i>P</i> < 0.001) and executive performance (Tower of London total moves, 52 [38] vs. 34 [21]; <i>P</i> < 0.001). Odor‐identification score was a significant predictor of abnormal performance on these cognitive tests after adjustment for age, sex, and disease characteristics in logistic regression models. The relationship between hyposmia, psychosis, and specific cognitive impairments may reflect the anatomic distribution of Lewy pathology and suggests that olfactory dysfunction could be a biomarker of additional extranigral disease. Future prospective studies are warranted to assess whether hyposmia, a very early feature of Parkinson's disease, might be used to predict the appearance of other common nonmotor symptoms. © 2011 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Funding agencies:</b> This work was supported by NIH grant K23 MH067894 (to D.W.).</p></note><note xml:id="fn2"><p><b>Relevant conflicts of interest</b>/<b>financial disclosures:</b> Dr. Morley has received travel funding from Teva Pharmaceutical Industries Ltd. Dr. Weintraub has served on a scientific advisory board for Boehringer Ingelheim; serves on the editorial board of <i>Movement</i> Disorders; has received speaker honoraria from Boehringer Ingelheim, ACADIA Pharmaceuticals, Novartis, Osmotica Pharmaceutical Corp., BrainCells Inc., Merck Serono, Sanofi‐aventis, and Pfizer Inc; and has received/receives research support from Avid Radiopharmaceuticals, Inc., Boehringer Ingelheim, National Institutes of Health (NIMH K23 MH067894 [PI], NINDS P50 NS053488‐01 [coinvestigator], NIA RO1AG031348 [site PI], and NINDS R01NS065087 [coinvestigator]), and from the Michael J. Fox Foundation for Parkinson's Research. Ms. Mamikonyan reports no disclosures. Dr. Siderowf serves on a scientific advisory board for, and has received speaker honoraria from, Teva Pharmaceutical Industries Ltd.; serves as a consultant for Supernus Pharmaceuticals, Inc.; and receives research support from Avid Radiopharmaceuticals, Inc., the NIH (NINDS U10 NS044451‐023 [Site PI], NINDS P50 NS053488‐01 [cocore leader and project leader], NINDS R43NS0636071 [site PI], and NINDS R01NS065087 [coinvestigator]), and from the Institute for Neurodegenerative Disorders. Dr. Duda serves on a grant review panel for the Michael J. Fox Foundation for Parkinson's Research; receives research support from the U.S. Department of Veterans Affairs (Merit Award [PI]), the Michael J. Fox Foundation, and the Samueli Institute; and holds stock in C.R. Bard, Inc., Celgene, Clarient, Inc., and Johnson & Johnson. Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Hyposmia and Neuropsychiatric Problems in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">James F.</namePart><namePart type="family">Morley</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Daniel</namePart><namePart type="family">Weintraub</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</affiliation><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</affiliation><affiliation>Mental Illness Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eugenia</namePart><namePart type="family">Mamikonyan</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paul J.</namePart><namePart type="family">Moberg</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</affiliation><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew D.</namePart><namePart type="family">Siderowf</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">John E.</namePart><namePart type="family">Duda</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA</affiliation><description>Correspondence: Philadelphia Veterans Administration Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-09</dateIssued><dateCaptured encoding="w3cdtf">2010-12-08</dateCaptured><dateValid encoding="w3cdtf">2011-04-18</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">53</extent><extent unit="words">5900</extent></physicalDescription><abstract lang="en">Hyposmia, psychiatric disorders, and cognitive problems are common nonmotor manifestations in Parkinson's disease, but how they are related remains unclear. We investigated the relationship between olfactory dysfunction and neuropsychiatric manifestations and performed a cross‐sectional study of 248 patients at two movement disorders clinics at academic medical centers. Psychiatric measures were the Geriatric Depression Scale‐15, Inventory of Depressive Symptomatology, State Anxiety Inventory, Apathy Scale, and Parkinson's Psychosis Rating Scale. Cognitive measures were the Mini–Mental State Examination, Hopkins Verbal Learning Test–Revised, Digit Span, Tower of London‐Drexel, and the Stroop Color Word Test. Olfaction was tested with the University of Pennsylvania Smell Identification Test. There was no significant association between olfaction and mood measures, but psychotic symptoms were more common in patients with olfaction scores below the median (30% vs. 12%; P < 0.001). Worse olfaction was associated with poorer memory (Hopkins Verbal Learning Test–Revised delayed recall items: mean [standard deviation], 6.2 [3.2] vs. 8.4 [2.8]; P < 0.001) and executive performance (Tower of London total moves, 52 [38] vs. 34 [21]; P < 0.001). Odor‐identification score was a significant predictor of abnormal performance on these cognitive tests after adjustment for age, sex, and disease characteristics in logistic regression models. The relationship between hyposmia, psychosis, and specific cognitive impairments may reflect the anatomic distribution of Lewy pathology and suggests that olfactory dysfunction could be a biomarker of additional extranigral disease. Future prospective studies are warranted to assess whether hyposmia, a very early feature of Parkinson's disease, might be used to predict the appearance of other common nonmotor symptoms. © 2011 Movement Disorder Society</abstract><note type="content">*Funding agencies: This work was supported by NIH grant K23 MH067894 (to D.W.).</note><note type="content">*Relevant conflicts of interest/financial disclosures: Dr. Morley has received travel funding from Teva Pharmaceutical Industries Ltd. Dr. Weintraub has served on a scientific advisory board for Boehringer Ingelheim; serves on the editorial board of Movement Disorders; has received speaker honoraria from Boehringer Ingelheim, ACADIA Pharmaceuticals, Novartis, Osmotica Pharmaceutical Corp., BrainCells Inc., Merck Serono, Sanofi‐aventis, and Pfizer Inc; and has received/receives research support from Avid Radiopharmaceuticals, Inc., Boehringer Ingelheim, National Institutes of Health (NIMH K23 MH067894 [PI], NINDS P50 NS053488‐01 [coinvestigator], NIA RO1AG031348 [site PI], and NINDS R01NS065087 [coinvestigator]), and from the Michael J. Fox Foundation for Parkinson's Research. Ms. Mamikonyan reports no disclosures. Dr. Siderowf serves on a scientific advisory board for, and has received speaker honoraria from, Teva Pharmaceutical Industries Ltd.; serves as a consultant for Supernus Pharmaceuticals, Inc.; and receives research support from Avid Radiopharmaceuticals, Inc., the NIH (NINDS U10 NS044451‐023 [Site PI], NINDS P50 NS053488‐01 [cocore leader and project leader], NINDS R43NS0636071 [site PI], and NINDS R01NS065087 [coinvestigator]), and from the Institute for Neurodegenerative Disorders. Dr. Duda serves on a grant review panel for the Michael J. Fox Foundation for Parkinson's Research; receives research support from the U.S. Department of Veterans Affairs (Merit Award [PI]), the Michael J. Fox Foundation, and the Samueli Institute; and holds stock in C.R. Bard, Inc., Celgene, Clarient, Inc., and Johnson & Johnson. Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>olfaction</topic><topic>nonmotor symptoms</topic><topic>psychiatric symptoms</topic><topic>cognitive symptoms</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>2051</start><end>2057</end><total>7</total></extent></part></relatedItem><identifier type="istex">C227001677EA3FFDB8C515D549210D0B6D05F7D6</identifier><identifier type="DOI">10.1002/mds.23792</identifier><identifier type="ArticleID">MDS23792</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001560 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001560 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:C227001677EA3FFDB8C515D549210D0B6D05F7D6
|texte= Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |